<status value="active"/> <date value="2021-07-19T17:03:53.324Z"/> <author> <name value="Brian S. Alper"/> </author> <publisher value="Computable Publishing LLC"/> <contact> <telecom> <system value="email"/> <value value="support@computablepublishing.com"/> </telecom> </contact> <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/> <description value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/> <variableDefinition> <description value="Control"/> <note> <text value="control group within study population: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia."/> </note> <variableRole value="population"/> <observed> <display value="standard of care medications alone"/> </observed> </variableDefinition> <variableDefinition> <description value="proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization"/> <variableRole value="outcome"/> <observed> <reference value="EvidenceVariable/5269"/> <type value="EvidenceVariable"/> </observed> </variableDefinition> <statistic> <description value="There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001)."/> <statisticType> <text value="Count of Participants"/> </statisticType> <quantity> <value value="21"/> <unit value="Participants"/> </quantity> <sampleSize> <knownDataCount value="47"/> </sampleSize> </statistic> </Evidence>

Generated Narrative: Evidence 6514

version: 1

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/6514

identifier: FEvIR Object Identifier/6514

name: OSFPreprint_PrimaryOutcomeMeasure_0_OG001

title: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint

status: Active

date: 2021-07-19 17:03:53+0000

author: Brian S. Alper:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition
description:
Control

note:
control group within study population: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.

variableRole: Population
observed: standard of care medications alone

variableDefinition
description:
proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization

variableRole: Outcome
observed: EvidenceVariable Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202)

statistic
description:
There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).

statisticType: Count of Participants
quantity: 21 Participants
SampleSizes
- KnownDataCount
* 47